Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Completed · Phase 2

Conditions studied: Uterine Fibroids

In brief

To determine the safety, pharmacokinetics and efficacy of 4 doses (3, 6, 12, 24 mg) of Proellex in premenopausal women with uterine fibroids confirmed by ultrasound. Drug will be administered vaginally.

Key facts

Study ID

NCT01451424

Run by

Repros Therapeutics Inc.

People needed

40

Starts

2012-02-01

Expected to finish

2013-01-01

Last updated by the study team

2014-08-29

Who can join

Age: 18 and older, up to 47. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed by ultrasound.
• Normal transvaginal ultrasound (other than for presence of fibroids)
• History of menstrual events occurring in regular cycles
• Agreement not to attempt to become pregnant
• Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit
• Ability to complete a daily subject diary
• Willing to discontinue hormonal contraceptives and consent to use of double barrier contraceptive techniques over the course of the study.
• Has a negative pregnancy test at the Screening and Baseline visits An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
• A Body Mass Index (BMI) between 18 and 39 inclusive
• Is available for all treatment and follow-up visits.

You may not qualify if…

• Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy
• Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 6 month study period
• Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5xULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).
• Received an investigational drug in the 30 days prior to the screening for this study
• Women with a history of PCOS
• Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
• Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera® in the preceding 6 months.
• Has an IUD in place
• Women currently using narcotics
• Women currently taking spironolactone
• Infectious disease screen is positive for HIV or Hepatitis A, B or C
• Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study

Where it is running

• Cetero Research — Miami Gardens, Florida, United States
• Advances in Health — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.